Denosumab Recommendations for Osteoporosis Treatment

Introduction to Denosumab Therapy

Denosumab is indicated for postmenopausal women and men with osteoporosis at high risk for fracture, administered as 60 mg subcutaneously every 6 months, and represents a first-line alternative when oral bisphosphonates are inappropriate or a preferred option for patients with renal impairment (eGFR 30-60 mL/min) 1, 2

The American College of Rheumatology conditionally recommends denosumab over bisphosphonates for patients ≥40 years at high risk of fracture 6
Denosumab is FDA-approved for men with osteoporosis at high risk for fracture 2
Denosumab is FDA-approved for glucocorticoid-induced osteoporosis in men and women at high risk receiving ≥7.5 mg prednisone daily for ≥6 months 3

Oral bisphosphonates remain the strongly recommended first-line therapy for most patients with osteoporosis, but denosumab should be used as first-line when oral bisphosphonates are not appropriate due to gastrointestinal contraindications, poor absorption concerns, medication adherence problems, or patient preference 1, 2, 3, 5
Denosumab is recommended as first-line therapy for patients with renal impairment (eGFR 30-60 mL/min) due to its lack of dose adjustment requirements and the need to avoid bisphosphonates in patients with eGFR <35 mL/min 6, 7

For very high-risk patients, anabolic agents (teriparatide, abaloparatide) are conditionally recommended over denosumab 6
In the treatment hierarchy for glucocorticoid-induced osteoporosis, denosumab is considered a fourth-line option after oral bisphosphonates, IV bisphosphonates, and teriparatide 3, 5

The American College of Rheumatology recommends against discontinuing denosumab without transitioning to another antiresorptive agent (typically a bisphosphonate) to prevent rebound vertebral fractures 6, 4
Denosumab carries a risk of severe, life-threatening, and fatal hypocalcemia, particularly in patients with advanced CKD (eGFR <30 mL/min) 7
Patients with weakened immune systems have an increased risk of serious infections, including cellulitis, skin infections, endocarditis, and infections requiring hospitalization 2

Denosumab requires continuous therapy due to rebound risk upon discontinuation, with benefits maintained for up to 10 years 1
Routine BMD monitoring during treatment is not recommended, as fracture reduction occurs independently of BMD changes 2, 4
Denosumab increases BMD more than oral bisphosphonates at all skeletal sites, but whether these BMD differences translate to superior fracture reduction remains unclear 4